Avita Medical Analyst Coverage Initiated by Zacks
(firmenpresse) - NORTHRIDGE, CA and CAMBRIDGE, UNITED KINGDOM -- (Marketwired) -- 06/19/13 -- Regenerative medicine Company (ASX: AVH) (OTCQX: AVMXY) is pleased to announce that Zacks Investment Research, Inc (), based in Chicago, IL, USA, has initiated coverage.
The news release and abbreviated report can be found on . The full initiation report can be viewed on the .
Avita Medical () develops and distributes regenerative products for the treatment of a broad range of wounds, scars and skin defects. Avita's patented and proprietary tissue-culture, collection and application technology provides innovative treatment solutions derived from a patient's own skin. The Company's lead product, ReCell® Spray-On Skin®, is used in a wide variety of burns, plastic, reconstructive and cosmetic procedures. ReCell is patented, CE-marked for Europe, TGA-registered in Australia, and SFDA-cleared in China. ReCell is not available for sale in the United States; in the U.S. ReCell is an investigational device limited by federal law to investigational use. A Phase III FDA trial is in process.
Contact:
Avita Medical Ltd.
Sharoni Billik
Investor Relations
Phone:+1 818 827-1675
Email:
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 19.06.2013 - 20:36 Uhr
Sprache: Deutsch
News-ID 271470
Anzahl Zeichen: 0
contact information:
Town:
NORTHRIDGE, CA and CAMBRIDGE, UNITED KINGDOM
Kategorie:
Medical Devices
Diese Pressemitteilung wurde bisher 247 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Avita Medical Analyst Coverage Initiated by Zacks"
steht unter der journalistisch-redaktionellen Verantwortung von
Avita Medical (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
